Sunday 18 October 2026 Export ESLA’s income statement to Excel — free account

Estrella Immunopharma, Inc.

ESLA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 329.2%, each against the same quarter a year earlier.

0.43 0.11 −20.37%

Follow ESLA

Alert me

Market cap: $23.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	199.78%	255.59%	373.21%	148.05%
ROA Full definition →		(250.19%)	(413.55%)	(434.36%)	(416.74%)
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		80.10%	110.09%	195.73%	134.74%
Free Cash Flow per Share Full definition →		0.05	(0.05)	(0.19)	(0.22)
Free Cash Flow Full definition →		2.02	(1.79)	(8.02)	(9.38)
Other line items
Cash ROIC Full definition →		(24.63%)	19.88%	239.84%	128.81%
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →		(0.22)	0.14	0.61	0.94
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		0.05	(0.05)	(0.19)	(0.22)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates